Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/7/2025 | $3.75 | Buy | Alliance Global Partners |
12/8/2023 | $3.00 | Buy | H.C. Wainwright |
9/25/2023 | $3.50 → $2.00 | Buy → Hold | Canaccord Genuity |
10/20/2021 | $13.00 | Buy | Canaccord Genuity |
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
SCHEDULE 13G/A - Quantum-Si Inc (0001816431) (Subject)
SD - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 29,940,119 shares of common stock (and common stock equivalents) at a purchase price of $1.67 per share, pursuant to a registered direct offering, resulting in gross proceeds of approximately $50 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about July 8, 2025, subject to the satisfaction of cus
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the placement of its Platinum® Pro instrument at the Broad Institute. This collaboration aims to support scientific innovation across oncology, therapeutics, and other key areas of biomedical research. This placement expands access to single-molecule protein sequencing within the Broad Institute and the Greater Boston life science ecosystem. Researchers in the region will now have the opportunity to collaborate on advanced applications such as high-resolution protein identification, as well as protein ba
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, announces participation in an expert panel during the upcoming GenomeWeb-hosted webinar, "From Raw to Reusable: Considerations for Data Integration and Real-World Standardization in Proteomics." When: June 20, 2025, at 8 a.m. PDT/11 a.m. EDT This one-hour webinar will explore critical strategies for improving the accessibility, integration, and standardization of data across proteomics platforms. Attendees will learn how to deposit data into public repositories, apply metadata annotation best practices, normalize cros
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2025 on Thursday, May 15, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personali
Achieves First Quarterly Revenue Over $1 Million Completes Capital Raises of $86 Million Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the fourth quarter and full year ended December 31, 2024. Press Release Highlights Reported revenue of $1.2 million for the fourth quarter of 2024 and $3.1 million for the full year 2024 (representing a 183% full year-over-year growth) Raised capital of over $86 million between the fourth quarter of 2024 and first week of 2025 (extending cash runway into the second half of 2027) Announced the launch of Platinum® Pro in January 2025, with shipp
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 3, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in numbe
SC 13D/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G - Quantum-Si Inc (0001816431) (Subject)
Alliance Global Partners initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.75
H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00
Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit